← Other Open Calls

Approaches to Increase Equitable Access to and Delivery of Quality of Care with Bispecific Antibodies for Patients with Multiple Myeloma 2023

Closing dates:

  • Topic: Support for the funding of projects that promote quality of care and best practice in the treatment of patients with relapsed/refractory Multiple Myeloma receiving treatment with a biospecific antibody.
  • Founder: Pfizer, S.A.
  • Budget: 1,250,000€, of which 250,000€/project will be awarded.
  • Duration: maximum 2 years.
  • Internal deadline: 30 May 2023.
  • Deadline: 1 June 2023.
  • Web link
  • Bases of the call